Manufacturing Facilities

VIRxSYS is the only company currently testing a lentiviral vector permitted for use by the FDA in Phase II clinical trials. Consequently, VIRxSYS is uniquely positioned to manufacture clinical-grade lentiviral vectors for therapies treating a wide range of life-threatening diseases.

VIRxSYS is initially focused on using lentiviral vectors in cellular therapies for HIV/AIDS.

VIRxSYS both manufactures clinical grade lentiviral vectors and performs cell processing for clinical trials at its Gaithersburg, Maryland facility. Our manufacturing facility includes two class 10,000 clean rooms for vector reproduction and patient cell processing. In addition, the company has a dedicated plasmid production room, a suite of quality control labs, and a variety of support rooms.

In addition to our manufacturing facilities, VIRxSYS has extensive research and devlopment facilites and capabilities dedicated to supporting the manufacturing and cinical trial initiatives, as well as to developing a pipeline of therapies for additional disease indications.

Leave a comment

Your email address will not be published.